Pulsed Tm:YAG vs Holmium laser kidney stone trial, NYU Langone Health
Summary
NYU Langone Health registered a new clinical trial (NCT07516106) on ClinicalTrials.gov comparing pulsed Tm:YAG laser versus Holmium laser for kidney stone treatment. The single-center randomized study will enroll approximately 100 participants and is sponsored by NYU Langone Health. The trial appears to be recruiting.
What changed
A new clinical trial comparing pulsed Thulium:YAG laser to Holmium laser for treating kidney stones was registered on ClinicalTrials.gov by NYU Langone Health. The randomized parallel-assignment study will assess efficacy and safety outcomes between the two laser modalities. Trial registration provides transparency and allows potential patients and referring physicians to identify ongoing research.
For urologists and healthcare institutions, this trial represents emerging evidence development in laser lithotripsy techniques. Patients with recurrent kidney stones may benefit from learning about this trial as a potential treatment option. Clinical investigators should ensure alignment with their own study portfolios and FDAAA registration obligations.
What to do next
- Monitor for trial results publication
- Review inclusion/exclusion criteria for potential referral opportunities
- Ensure compliance with FDAAA 801 registration requirements if applicable
Source document (simplified)
Show glossary
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.